Hi AllGot to say that the presentation was pretty good and...

Hi All

Got to say that the presentation was pretty good and transparent running over 8 pages. It is on Alpha and you can probably get the audio which runs for about 30mins. However i will just note those items that may be of interest to SUDA shareholders and relate to Zolpimist

In current quarter Aytu posted all time high revenue of $1.8m an increase of 71%for same quarter last year and a 25% growth from the previous quarter. 

This quarter we expanded our commercial portfolio by launching Zolpimist into its first full quarter. Upon acquiring Zolpimist we adjusted the wholesale price to market levels and we manage various aspects of the supply chain and the wholesale channel and began some early initial field promotion.

In Q3 we expect to have meaningful revenue going forward with regular prescribing in pharmacy script filling.

With Zolpimist the message of oral spray convenience and rapid absorption into the bloodstream resonates with physicians.

The addition of Zolpimist and Tuzistra XR have broadened our portfolio nicely and provide great leverage with our nationwide sales force. A strong differentiated product portfolio is what we think will drive the most value which will grow.

Our year to year revenue of $3.2M is 52% greater than the same period last year. In addition to revenue growth we also reported record gross profit of approx $1.3M for Q2 double what was reported for Q2 last year. 

We integrated Zolpimist into the portfolio and substantially increased the strength of the balance sheet. We also expect a meaningful revenue contribution from Zolpimist and MOXSYS this quarter whist Natesto continues to grow.We are a growth company as evidenced by 3 consecutive high growth quarters and we can contnue to grow through our continued commercial execution.

Thats all folks.

kippax
PS For what its worth it looks very promising for Zolpimist that is being sold by a team with multiple offerings.If the sales are good they will certainly look for further markets.